Cambridge Antibody Technology cambridgeantibody.com


Public list: Pharma Startups (4743) Cancer Therapeutics (1148)

Cambridge Antibody Technology is engaged in the development of human monoclonal antibodies as new treatments for disease, having developed a pipeline of human monoclonal antibodies. HUMIRA, an antibody for the treatment of rheumatoid arthritis, developed in collaboration with Abbott, is on the market. Cambridge Antibody Technology was acquired by AstraZeneca for cash in 2006.

Cambridge Antibody Technology is engaged in the development of human monoclonal antibodies as new treatments for disease, having developed a pipeline of human monoclonal antibodies. HUMIRA, an antibody for the treatment of rheumatoid arthritis, devel...Show all

Company (Acquired)

Phone:

Fax:




United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cambridge Antibody Technology $0M May 15, 2006
See all 18 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cambridge Antibody Technology Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

HNC Software

Fallbrook, California, United States
AcquiredHNC Software is a provider of Customer Insight software that enables companies to acquire, manage and retain customers. HNC's decision management and customer analytics technology analyze both structured and unstructured data so companies can derive value from all information. The company's sophisticated software is used in the telecommunications, financial services, insurance and e-commerce industries.Login to see details

PharmAthene

Annapolis, Maryland, United States
Alive / ActivePharmAthene's primary objective is the development of effective countermeasures to a range of biological and chemical threats having potential lethal effects for the military or civilian populations. The Company is developing Valortim, an anthrax monoclonal antibody, in collaboration with Medarex, Inc. for pre- and post exposure prophylaxis and treatment, as well as Protexia, a recombinant human butyrylcholinesterase for treatment following exposure to chemical nerve agents.Login to see details
See all 18 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Antibodies against human or mouse il-21 receptor Mar 12, 2004 Feb 24, 2009 Patent